
# IN VITRO DISSOLUTION TESTING FOR NANO FORMULATIONS








#### PROF. PADMA V. DEVARAJAN

Dept. of Pharmaceutical Sciences and Technology
Institute of Chemical Technology (ICT)
Deemed University, Elite status and Centre of Excellence (GOM),
Mumbai 400 019, INDIA
E-mail: pvdevarajan@gmail.com

**DISSO INDIA 2017- MUMBAI JUNE 8-9, 2017** 



### NANOCARRIERS IN NANOMEDICINE





### **ADVANTAGE - NANOMEDICINE**

- **✓ TARGETTED DELIVERY**
- ✓ ENHANCED BIOAVAILABILITY & EFFICACY
- **✓ DECREASED SYSTEMIC TOXICITY**













# Nanosystems and Need for *in vitro*Dissolution testing

Nanosystems are promising



Unavailability of standardized in vitro dissolution method





Urgent Need to develop Standardized Testing Methods



## CHALLENGES IN DISSOLUTION METHOD FOR NANOMEDICINES



Size & Separation

 Difficulty in Separation of NP from medium

Complex System

- Complexity of System type
- Target specific release
- Environment specific release (pH, temperature)
- Programmed Release
- Biorelevant media



## DISSOLUTION METHODS FOR NANOMEDICINES




#### **DISSOLUTION METHODS**


■ Sample & Separation methods



☐ Membrane Diffusion (Dialysis Sac) methods




Others (Micro dialysis, Dynamic dissolution& 2 stage reverse dialysis)





### **MODIFIED OFFICIAL APPARATUSES**

- Constant Volume
  - USPI&II



- Continuous Flow Methods
  - USP IV






#### **SAMPLE & SEPERATION METHODS**

- NP directly added in medium & separation techniques applied
- Drug content in supernatant or filtrate is analyzed







**Ultracentrifugation** 



Key parameters : Sample separation technique


**Agitation conditions** 



#### **SAMPLE & SEPARATION METHODS**

#### **Pressure Ultrafiltration**

- Completely separate Nanoparticles from release media within 5 min
- Prevent Clogging of filter pores



**SCHEMATIC** 

#### **Syringe Filtration**

• Use of Syringe filters with smaller pore size (0.1 to 0.02  $\mu$ m) has been used







## DISADVANTAGES OF SAMPLE & SEPARATION METHODS



Difficulty in separation of NP from media though high external energy applied



Long-time & High speed can result in destabilization of system (e.g. Nanoemulsion & Liposome)




Drug release continues during separation process, which can lead to erroneous results



#### **DYNAMIC DISSOLUTION**

### ADVANCED SAMPLE AND SEPARATE METHOD



Utilize ion- or drug-selective electrodes to monitor the dissolution/release profiles of electroactive drugs

Not suitable for non-electroactive drugs




### **DIALYSIS METHODS**

FIXED VOLUME




### KEY PARAMETERS INFLUENCING DRUG RELEASE IN DIALYSIS METHODS



#### **Agitation Conditions**



Ratio between Donor & acceptor cell Volume Inside Volume 6 to 10 fold less than medium volume




Molecular Weight Cut-Off (MWCO) of membrane

MWCO 100 times more than drug MW




## MEMBRANE DIFFUSION METHODS (DIALYSIS BAG)


Nanosystems separated from the release medium through dialysis membranes that are permeable to the free drug but impermeable to the nanosystems



**Dialysis Sac Method** 




Reverse Dialysis Sac Method



Side-by-Side-Dialysis




# DEVELOPMENTS IN DISSOLUTION METHOD





## ROTATING DIALYSIS CELL FOR PARENTERAL DEPOT FORMLATIONS




BASKET MODIFIED INTO A DIALYSIS CELL


K. Schultz et al, Int. J. Phar., 1997



## ROTATING DIALYSIS CELL FOR PARENTERAL DEPOT FORMLATIONS




Release profiles at pH 5.00 for three different volumes of formulation. Flupentixol NP depot



Release profiles for 5 ml of formulation at three different pH values.



### ADAPTATION OF DIALYSIS AND USP TYPE I




BASKET MODIFIED INTO A DIALYSIS CELL

Yuan Gao et al, BioMed Res. Inter., 2013




### ADAPTATION OF DIALYSIS AND USP TYPE I



In vitro release curves of RIF-NPs using the modified cylinder method. (a) RIF-Gel-NPs with drug loading of 21.6% w/w in the presence and absence of trypsin; (b) RIF-Gel-NPs with drug loading of 56.7% w/w in the presence and absence of trypsin;




### ADAPTATION OF DIALYSIS AND USP TYPE I & II (Phamatest)



- Pharma Test offers the "dispersion releaser"
- High sensitivity for fluctuations in release rate
- Works well for compounds with poor, moderate and good solubility



### ADAPTATION OF DIALYSIS AND USP TYPE I & II (Phamatest)




**SCHEMATIC** 

Patent No. DE102013015522.3



### ADAPTATION OF DIALYSIS AND USP TYPE I & II (Phamatest)



- · Free drug, dispersion releaser
- Free drug, dialysis bag
- Io SR formulation 1 /2

Setup USP2 / dialysis bag or

dispersion releaser

pH 7.2


Medium phosphate buffer saline

10% FCS

Batch-to-batch reproducibility
Useful for Low solubility API release study



## ADAPTATION OF DIALYSIS AND CONTINUOUS FLOW CELL



1 rubber seals

2 glass lid

3 release medium outlet

4 release medium inlet

5 release device

A a flask containing fresh release medium

B a peristaltic pump


C the proposed release device

D a sampling flask



## ADAPTATION OF DIALYSIS AND CONTINUOUS FLOW CELL FOR NLC

Conventional Dialysis bag method with Proposed flow apparatus



Diego Fontana de Andrade et al, AAPS PharmSciTech, 2015



## DISADVANTAGES OF DIALYSIS METHODS

Lack of adequate agitation inside membrane

Absence of sink condition

(fixed volume)

Hindrance to drug diffusion through membrane

Disadvantages of Dialysis Methods

Reverse system causes high dilution of Nano system thus medium loses its discriminatory ability



## CONTINUOUS FLOW THROUGH CELL TYPE IV

This method has been widely used to investigate drug release from microspheres

But Nanoparticulate systems have very small particle size (<100nm), challenging to test their release in USP IV.


#### **CHALLENGE:**

- •NP clog the filter leading to slow flow rates and high pressure buildup in the system
- Pass through filters, thus resulting in erroneous data.

**SOLUTION:** novel Dialysis Adaptor is introduced in USP type IV



## CONTINUOUS FLOW THROUGH CELL TYPE IV





## CONTINUOUS FLOW THROUGH CELL TYPE IV





## CONTINUOUS FLOW THROUGH CELL TYPE IV - DIALYSIS CELL







- ✓ High Discriminative power
- ✓ Avoided Filter clogging
- ✓ Avoided violation of sink conditions
- ✓ Avoided lack of agitation




### **CASE STUDIES**

# USP APPARATUS IV WITH DIALYSIS CELL



# INORGANIC NANOPARTICLES OF SALMON CALCITONIN USP IV




- 98 % of SCT high molecular weight drug (MW ~3000) in 1 hr indicates dialysis membrane not rate limiting
- Sustained release seen with SCT NPs




## AMPHOTERICIN B NANOSYSTEM USP TYPE IV- LIPOMER vs SLN

Volume of Media-100mL Flow rate-6mL/min



Sample volume-1mL Aliquot volume-1mL





- SLN 23.50±3.22% AmB release after 24h
- Lipomer 39.98±5.74 % AmB release after 24h
- SLN 26.26±2.70% AmB release after 24h
- Lipomer 41.38±0.45% AmB release after 24h

**DISCRIMINATION BETWEEN TWO NANOSYSTEMS OBSERVED** 



### BUPARVAQUONE SLN USP TYPE I vs IV





USP I – LOWER DRUG RELEASE DUE TO ABSENCE OF SINK CONDITION USP IV – COMPLETE RELEASE AND LOWER STANDARD DEVIATIONS



#### **SUMMARY**

- USP IV WITH DIALYSIS CELL APPEARS PROMISING
  - DISPOSABLE DIALYSIS CELLS OVERCOME OPERATIONAL DIFFICULTIES OF THE DIALYSIS CELL
- USP II MODIFIED APPARATUS PROMISING
  - COULD LACK SINK CONDITION FOR POORLY SOLUBLE DRUGS



### **FUTURE PERSPECTIVES**

- SYSTEMS THAT ADDRESS SPECIFIC REQUIREMENTS OF NANOSYSTEMS
- BIORELEVANT DISSOLUTION MEDIA
  - No release in circulation
  - Release prediction at site of delivery
- COST EFFECTIVE STRATEGIES MAY BE EXPLORED



## PROF. DEVARAJAN'S RESEARCH GROUP





#### **INSTITUTE OF CHEMICAL TECHNOLOGY**







Deemed University, Elite status and Centre of Excellence (GOM)



### **ACKNOWLEDGEMENTS**

- SOTAX INDIA PVT. LTD., FOR USP IV WITH DIALYSIS CELL
- Amit Lokhande

